Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Risk factor of cholelithiasis is rapid weight loss after bariatric surgery and change in the gallbladder function which is secondary to surgery. Many observational studies support this fact, and a high incidence of 28% -71% after gastric bypass surgery (RYGB) was reported in them. According to another publication, the incidence of gallbladder diseases is 5-36% after jejunoileal bypass surgery and 2.8-36% after gastric bypass surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: HaEmek Medical Center, Israel
• Treatments: Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Candidates for sleeve gastrectomy or gastric bypass surgery due to morbid obesity with BMI range of 40 to50.

• Aged 18 to 65.

• No presence of gallstones.

• Patients who have signed the consent form.

Exclusion Criteria:

• Minors,

• Pregnant women,

• Age over 65,

• Sensitive to Ursodiol,

• Gallstones,

• Biliary tract pathologies,

• Gallbladder wall thickening,

• Patients after cholecystectomy,

• Patients participating in another clinical trial.